HitGen and BioAge Labs Begin Phase 2 Trial for BGE-102, A Breakthrough Cardiovascular Treatment
In a groundbreaking development, HitGen Inc. and its partner, BioAge Labs, have announced the commencement of a Phase 2 trial for BGE-102, a novel oral NLRP3 inhibitor designed for cardiovascular risk reduction. This signifies a pivotal moment in their collaborative efforts to innovate treatments for cardiometabolic diseases.
Scheduled trials will be part of the QUELL-CV study, which aims to identify the optimal dosage for subsequent phases and assess the safety and effectiveness of BGE-102. Initial results from the trial are expected by the latter half of 2026. BGE-102 is derived from a compound discovered using HitGen's advanced DNA-Encoded Library (DEL) technology, representing a significant achievement for both companies involved.
The innovative NLRP3 inhibitor is intended as a once-daily oral treatment targeting cardiovascular risks, and its initial Phase 1 trial showed promising results, indicating its potential to reduce high-sensitivity C-reactive protein (hsCRP) levels substantially. The QUELL-CV trial involves a randomized and controlled design, ensuring rigorous examination of BGE-102's efficacy.
Dr. Jin Li, CEO of HitGen, expressed enthusiasm about reaching this trial phase, highlighting how the DEL platform can generate novel small-molecule leads against challenging targets. He emphasized the power of collaboration with BioAge Labs and the shared goal of advancing healthcare solutions.
BioAge's CEO, Kristen Fortney, also praised the advancement of BGE-102 to Phase 2, noting how the team's medicinal chemistry initiatives successfully translated DEL-derived hits into a promising therapeutic. The collaboration showcases HitGen's expertise in drug discovery, having partnered with over 600 clients globally and contributed to thousands of innovative drug development projects.
This partnership has previously resulted in significant achievements, including joint publications and patents concerning compounds generated through DEL screening, illustrating the fruitful synergy between the two companies.
With the stakes set high for the QUELL-CV trial, the outcomes could offer vital insights into cardiovascular risk management, potentially positioning BGE-102 as a best-in-class therapy with its unique mechanism of action. The continued collaboration between HitGen and BioAge Labs not only aims to propel BGE-102 forward but also to explore new avenues in drug discovery and development, targeting various metabolic challenges associated with aging.
Overall, this development underscores the critical role of innovative approaches in addressing unmet medical needs and paving the way for new therapeutic solutions in cardiometabolic disease management. As researchers and healthcare professionals keep a close watch on the trial, the potential implications for patient care are immeasurable, offering hope for effective treatments for cardiovascular conditions rooted in biological aging and inflammation.
Scheduled trials will be part of the QUELL-CV study, which aims to identify the optimal dosage for subsequent phases and assess the safety and effectiveness of BGE-102. Initial results from the trial are expected by the latter half of 2026. BGE-102 is derived from a compound discovered using HitGen's advanced DNA-Encoded Library (DEL) technology, representing a significant achievement for both companies involved.
The innovative NLRP3 inhibitor is intended as a once-daily oral treatment targeting cardiovascular risks, and its initial Phase 1 trial showed promising results, indicating its potential to reduce high-sensitivity C-reactive protein (hsCRP) levels substantially. The QUELL-CV trial involves a randomized and controlled design, ensuring rigorous examination of BGE-102's efficacy.
Dr. Jin Li, CEO of HitGen, expressed enthusiasm about reaching this trial phase, highlighting how the DEL platform can generate novel small-molecule leads against challenging targets. He emphasized the power of collaboration with BioAge Labs and the shared goal of advancing healthcare solutions.
BioAge's CEO, Kristen Fortney, also praised the advancement of BGE-102 to Phase 2, noting how the team's medicinal chemistry initiatives successfully translated DEL-derived hits into a promising therapeutic. The collaboration showcases HitGen's expertise in drug discovery, having partnered with over 600 clients globally and contributed to thousands of innovative drug development projects.
This partnership has previously resulted in significant achievements, including joint publications and patents concerning compounds generated through DEL screening, illustrating the fruitful synergy between the two companies.
With the stakes set high for the QUELL-CV trial, the outcomes could offer vital insights into cardiovascular risk management, potentially positioning BGE-102 as a best-in-class therapy with its unique mechanism of action. The continued collaboration between HitGen and BioAge Labs not only aims to propel BGE-102 forward but also to explore new avenues in drug discovery and development, targeting various metabolic challenges associated with aging.
Overall, this development underscores the critical role of innovative approaches in addressing unmet medical needs and paving the way for new therapeutic solutions in cardiometabolic disease management. As researchers and healthcare professionals keep a close watch on the trial, the potential implications for patient care are immeasurable, offering hope for effective treatments for cardiovascular conditions rooted in biological aging and inflammation.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.